Printer Friendly Version View printer-friendly version
<< Back
Natera to Present at the UBS Virtual Global Healthcare Conference

SAN CARLOS, Calif., May 13, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the UBS Virtual Global Healthcare Conference on Monday, May 18, 2020 at 12:50 p.m. PT (3:50 p.m. ET).

Mike Brophy, Chief Financial Officer, will provide an overview of the company and discuss recent business activities. 

Access to the live webcast and subsequent archived presentation will be available at investor.natera.com.

About Natera
Natera is a global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide with a focus on reproductive health, oncology, and organ transplantation. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif. It offers a host of proprietary genetic testing services to inform physicians who care for pregnant women, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit natera.com. Follow Natera on LinkedIn.

Contacts
Investor Relations: Mike Brophy, CFO, Natera, Inc., 650-249-9090
Media: Paul Greenland, VP of Corporate Marketing, Natera, Inc., pr@natera.com

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/natera-to-present-at-the-ubs-virtual-global-healthcare-conference-301058341.html

SOURCE Natera, Inc.

Footer disclaimer

Footer disclaimer

© Natera 2020. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.